Evidence map›Paper›PMID 29615458›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.

Nicholas Pulliam, Fang Fang, Ali R Ozes, Jessica Tang, Adeoluwa Adewuyi, Harold Keer, John Lyons, Stephen B Baylin, Daniela Matei, Harikrishna Nakshatri and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 1 synthesis or guideline pooled it, 126 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Nicholas PulliamMolecular and Cellular Biochemistry Department, Indiana University, Bloomington, Indiana.
Fang FangMedical Sciences Program, Indiana University School of Medicine, Bloomington, Indiana.
Ali R OzesMolecular and Cellular Biochemistry Department, Indiana University, Bloomington, Indiana.
Jessica TangMedical Sciences Program, Indiana University School of Medicine, Bloomington, Indiana.
Adeoluwa AdewuyiDepartment of Radiation Oncology, School of Medicine, University of Maryland, Baltimore, Maryland.
Harold KeerAstex Pharmaceuticals, Inc., Pleasanton, California.
John LyonsAstex Therapeutics Limited, Cambridge, United Kingdom.
Stephen B BaylinDepartment of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland.
Daniela MateiDepartment of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Harikrishna NakshatriDepartment of Surgery, Indiana University School of Medicine, Indianapolis, Indiana.
Feyruz V RassoolDepartment of Radiation Oncology, School of Medicine, University of Maryland, Baltimore, Maryland.
Kathy D MillerDepartment of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.
Kenneth P NephewMolecular and Cellular Biochemistry Department, Indiana University, Bloomington, Indiana. knephew@indiana.edu.
Indiana University School of MedicineIndiana University Bloomington · USIndiana University – Purdue University Indianapolis · US

Funding

Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3M
An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian CancerR01CA182832 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MATEI, DANIELA E, NEPHEW, KENNETH P · 2014 to 2018
$1.6M
NCATS NIH HHS UL1 TR001108NCI NIH HHS R01 CA182832
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MutationAnimalsAntineoplastic Combined Chemotherapy ProtocolsBiomarkersBRCA1 ProteinBRCA2 ProteinCell Line, TumorCyclic AMPCyclic AMP-Dependent Protein KinasesDisease Models, AnimalEpigenesis, GeneticFemaleHumansMiceOvarian NeoplasmsPhthalazinesBiomarkersBRCA1 ProteinBRCA2 ProteinCyclic AMPCyclic AMP-Dependent Protein KinasesPhthalazinesPoly(ADP-ribose) Polymerase InhibitorsReactive Oxygen Speciestalazoparib

Identifiers

PMID29615458
PMCPMC7003715
OpenAlexW2795391593

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.